Skip to main content
. 2020 Jun 20;146(11):3003–3012. doi: 10.1007/s00432-020-03289-5

Table 3.

Adverse events as assessed by CTCAE v4.03 after first and after overall CS-PHP

After 1st CS-PHP Overall
n % n %
Platelet concentrate 12 20.3 18 30.0
Erythrocyte concentrate 11 18.6 19 31.7
Grade 3 thrombopenia 15 25.0 28 46.7
Grade 4 thrombopenia 14 23.3 20 33.3
Grade 3 anemia 19 31.7 26 43.3
Grade 4 anemia 0 0 1 1.7
Grade 3 leucopenia 4 6.7 8 13.3
Grade 4 leucopenia 7 11.7 11 18.3
Grade 3 AST increase 11 18.3 20 33.3
Grade 4 AST increase 7 11.7 9 15.0
Grade 3 ALT increase 4 6.7 12 20.0
Grade 4 ALT increase 2 3.3 4 6.7
Grade 3 hyperbilirubinemia 5 8.3 8 13.6
Grade 4 hyperbilirubinemia 1 1.7 1 1.7
Grade 3 hypoalbuminemia 4 8.7 8 15.4
Grade 4 hypoalbuminemia 0 0 0 0